Speaker(s): 

Ed Zuroweste, MD, TB Medical Consultant, PA Department of Health TB Program - has nothing to disclose.

Moderator(s): 

Stanley Martin, MD, Staff Physician, Geisinger - has nothing to disclose.

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

•Determine the preference of using Interferon-Gamma Release Assay’s (IGRA) for screening high risk individuals for Tuberculosis (TB)

•Recognize and be able to use the new treatment options for both Latent Tuberculosis Infection (LTBI) and active TB

•Recognize the global, national, and state prevalence of Tuberculosis

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Stefanie Leader, DO; Stanley Martin, MD; Dan Dometita, DO; Malachi Courtney, MD; Eric Hossler, DO; Stacey Coolbaugh, RDN; and Donald Wieder, PA-C have no identified disclosures. 

CE Committee Member/CE content reviewers Andrea Dimattia, EdD and Thomas Davis, MD; have nothing to disclose.

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant.